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Abstract
Background: Poland Syndrome (PS) is a rare congenital disorder presenting with agenesis/hypoplasia of the
pectoralis major muscle variably associated with thoracic and/or upper limb anomalies. Most cases are sporadic, but
familial recurrence, with different inheritance patterns, has been observed. The genetic etiology of PS remains
unknown. Karyotyping and array-comparative genomic hybridization (CGH) analyses can identify genomic
imbalances that can clarify the genetic etiology of congenital and neurodevelopmental disorders. We previously
reported a chromosome 11 deletion in twin girls with pectoralis muscle hypoplasia and skeletal anomalies, and a
chromosome six deletion in a patient presenting a complex phenotype that included pectoralis muscle hypoplasia.
However, the contribution of genomic imbalances to PS remains largely unknown.
Methods: To investigate the prevalence of chromosomal imbalances in PS, standard cytogenetic and array-CGH
analyses were performed in 120 PS patients.
Results: Following the application of stringent filter criteria, 14 rare copy number variations (CNVs) were identified
in 14 PS patients in different regions outside known common copy number variations: seven genomic duplications
and seven genomic deletions, enclosing the two previously reported PS associated chromosomal deletions. These
CNVs ranged from 0.04 to 4.71 Mb in size. Bioinformatic analysis of array-CGH data indicated gene enrichment in
pathways involved in cell-cell adhesion, DNA binding and apoptosis processes. The analysis also provided a number
of candidate genes possibly causing the developmental defects observed in PS patients, among others REV3L, a
gene coding for an error-prone DNA polymerase previously associated with Möbius Syndrome with variable
phenotypes including pectoralis muscle agenesis.
Conclusions: A number of rare CNVs were identified in PS patients, and these involve genes that represent
candidates for further evaluation. Rare inherited CNVs may contribute to, or represent risk factors of PS in a
multifactorial mode of inheritance.
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Background
Poland Syndrome (PS, MIM173800) is a congenital dis-
order of the pectoralis major muscle. PS patients present
with pectoralis muscle agenesis/hypoplasia, more fre-
quently on the right side. PS can be associated with a vari-
able degree of ipsilateral thoracic and/or upper limb
anomalies [1, 2]. Incidence of PS has been reported be-
tween 1/20,000 and 1/30,000 births with a higher preva-
lence in males [3, 4]. Today, PS etiopathogenesis is still
unknown. One of the most common assumptions is that
isolated pectoralis major muscle defects are included in
the spectrum of anomalies postulated to result from dis-
ruption of blood supply in the embryonic subclavian and
vertebral arteries [5, 6]. Alternatively, PS may be due to
the involvement of genes regulating embryonic develop-
ment of pectoral girdle [7]. Familial recurrence was ob-
served in about 10% of cases with different inheritance
patterns including autosomal dominant with incomplete
penetrance, autosomal recessive, and X-linked [1]. The
presence of different genes whose mutations may account
for clinical differences among subgroups of patients and
for the different inheritance patterns observed could be
hypothesized. Two recently reported cases of de novo de-
letions contribute to support the genetic origin of PS and
suggests the involvement of the deleted regions in PS
pathogenesis. A deletion of chromosome 11q12.3 in
monozygotic twins both affected by PS [8] and a large de-
letion of chromosome 6q21-q22.1 in a patient with a com-
plex phenotype mainly characterized by mental disability
and PS [9]. Genomic imbalances and copy number vari-
ants (CNV) represent a main source of genetic variation
in humans and contribute to different congenital and neu-
rodevelopmental defects [10–14]. However, the contribu-
tion of genomic imbalances to a broader number of PS
patients has not been systematically studied. In this study,
we performed karyotyping and array-CGH analysis of a
large cohort of PS patients to discover novel chromosomal
regions associated with this condition.
Methods
Patients
The present cohort comprises 120 patients with pectora-
lis muscle agenesis/hypoplasia, either isolated or with as-
sociated anomalies (clinical data are summarized in
Table 1). Control population (in-house controls) com-
prises 200 patients affected by various disorders (mainly
intellectual disabilities) admitted to the Medical Genetics
Unit, Gaslini Institute, Genoa, Italy, between January
2008 and December 2015, and their healthy parents for
a total of 600 control individuals with no clinically evi-
dent pectoralis muscle abnormalities nor other features
usually reported to be associated with PS.
All patients were evaluated by a multidisciplinary team
enclosing surgeons, radiologists, orthopaedic surgeons,
and clinical geneticists to get a complete evaluation of the
patient phenotype. The presence of additional anomalies
as dysmorphic signs, and the presence of associated syn-
dromic features were carefully evaluated by a team of clin-
ical geneticists with experience in dysmorphology. PS
specific features and the possible presence of additional
anomalies were investigated in details by physical examin-
ation, followed by radiological/ultrasound examination.
Karyotyping and array-CGH analyses
Chromosome analysis was carried out on GTG-banded
chromosomes at a resolution of 550 bands. Array-CGH
analysis was performed using a genomic oligonucleotide-
array with 13 kb (AMADID 022060) or 22 kb (AMADID
014698) (Human Genome Microarray Chip; Agilent
Technologies, Palo Alto, CA, USA). Array data were ana-
lyzed using the Agilent Genomic Workbench Lite Edition
Software 6.5.0.18. Aberration segments were reviewed
using GRCh37 hg19 of UCSC Genome Browser (http://
genome.ucsc.edu/index.html). We annotated all detected
copy number variations (CNVs) and CNV-encompassed
Table 1 Summary of clinical data of all 120 patients





















Upper limb anomalies 57
Classic brachysyndactyly 24
Hypoplasia of upper limb and/or hand 28
Cerebellar malformations and intellectual disabilities 1
Poland-Möbius syndrome 1
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genes across public databases: Genomic Variants Database
(DGV) (http://dgv.tcag.ca/dgv/app/home), DECIPHER
(https://decipher.sanger.ac.uk/), Clinical Genome Re-
source (ClinGen) and ISCA (http://www.clinicalgen-
ome.org), OMIM (http://www.omim.org), PubMed
(http://www.ncbi.nlm.nih.gov/pubmed), and databases of
mouse (MGD)(http://www.informatics.jax.org) and zebra-
fish (ZFIN) (ZFIN, http://zfin.org) models.
CNV annotation
All detected CNVs were tested for inheritance by
hybridization of the parental DNA with the same array
platform. A CNV was classified as unreported if it dif-
fered from those already reported for involving one
more gene and/or if it differed by at least 100 kb on ei-
ther side or by a total of 100 kb on both sides. To assess
the clinical significance of the detected CNVs, we
followed the recommended steps from Miller and coll.
[15]. All imbalances classified as benign in the ClinGen
and/or found in our internal database of healthy individ-
uals were considered to be benign and excluded from
further analysis. The remaining CNVs were classified
into groups. Group I contains genomic imbalances clas-
sified as being variants of uncertain clinical significance
(VOUS) because of their unclear possible pathogenicity.
CNVs were further classified as VOUS likely pathogenic,
if including genes with a possible correlation to the
phenotype, or simply VOUS, those CNVs for which clin-
ical interpretation remains uncertain. Group II contains
pathogenic CNVs overlapping critical regions of known
microdeletions or microduplications and/or involving
genes already described as causing a phenotype. These
CNVs are found in the publicly available DECIPHER
(https://decipher.sanger.ac.uk/) and ISCA (www.clinical-
genome.org) databases and in published literature. Only
VOUS, and VOUS likely pathogenic variants were fur-
ther investigated.
Real-Time genomic qPCR
Validation by an independent assay, i.e. quantitative
polymerase chain reaction (qPCR), was obtained for de
novo and/or unreported CNVs identified in PS patients
(Additional file 1) according to established protocols
[16]. Briefly, DNA from the patients was analyzed to-
gether with DNA from one healthy adult used as con-
trol. Primers were designed to amplify a region lying
inside the deletion or duplication and one region flank-
ing the CNV. A region on chromosome 12 encompass-
ing the GAPDH gene (NM_002046.3) was used as
internal control to determine copy number and
normalize primer efficiency (primer sequences are avail-
able on request). qPCR was performed using the iCycler
(Biorad, Hercules, CA) with Sybr Green, and the com-
parative DDCt method as previously described [16, 17].
Bioinformatics and network analysis of genes included
within CNVs
We searched for mutations affecting the identified CNV-
genes, and possibly associated to genetic disorders and/
or anomalous phenotype, through available public data-
bases: OMIM, PubMed, UCSC, GeneCard (http://
www.genecards.org/), ClinVar (https://www.ncbi.nlm.-
nih.gov/clinvar/).
We used GeneCodis3 [18] to unveil enrichment of an-
notations. Genomic coordinates of altered regions were
used to retrieve CNV overlapping genes from the hg19
RefSeq track of the UCSC genome browser. All the genes
obtained from either duplicated or deleted regions were
used as input in GeneCodis (Additional file 2). This tool
allows the classification of genes according to their puta-
tive biological function by screening the Gene Ontology
(GO), OMIM, Panther Pathway, and KEGG Pathway. In
the analysis, the hypergeometric test was applied followed
by the false discovery rate correction (FDR) with a cut-off
of 5% to determine which annotations were significantly
enriched. For GO analysis, various hierarchical levels of
the annotation data structure were used. A graphical rep-
resentation of the GeneCodis analysis results and of the
possible interrelationship among the CNV-genes was ob-
tained by using Cytoscape tool [19].
Results
Clinical phenotypes
Clinical data from 120 sporadic PS patients, 115 new
and 5 already reported [1, 8, 9] were collected and
their clinical features summarised in Table 1. Rarely,
PS patients can show associated anomalies involving
other structures/organs [20]. Overall, no dysmorphic
signs or other anomalies were observed in these pa-
tients but one, who presented with associated Möbius
syndrome features. This patient was referred to the Med-
ical Genetics Unit of Istituto Gaslini Genoa at the age of
9 months showing the following anomalies: weight and
head circumference < 3rd centile; length at 5th centile; right
facial nerve paralysis; epicanthic folds; micrognatia and
cleft palate (Pierre Robin sequence, MIM261800); right
abducens nerve paralysis; right auditory nerve paralysis;
right upper limb hypoplasia; flexion deformity of the left
elbow and the left wrist.
Genomic rearrangements identified in Poland syndrome
patients
Karyotyping and array-CGH analyses were performed in
all patients. This survey led to the identification of 14
different heterozygous chromosome anomalies in 14 dif-
ferent patients, notably the same alteration was never re-
ported in more than one patient (Table 2). The
duplication of patient PS14 and the deletion of patient
PS15 overlapped the same 1.8Mbp region on
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chromosome 16p13.1 causing a dosage imbalance of the
same 12 RefSeq genes. Smaller deletions affecting
chromosome 16p13.1 were found in two in-house con-
trols, and chromosome 16p13.1 deletions and 16p13.1
duplications were reported in patients with intellectual
disabilities [21] and autism [22], respectively, without
any PS-associated clinical sign. Except for CNVs involv-
ing chromosome 16p13.1 region, CNV data of PS pa-
tients and in-house controls did not reveal any shared
CNVs. The deletion of patient PS6 overlaps the AUTS2
gene, a susceptibility candidate gene for autism that is
not related to PS-involved tissues.
The parental origin was assessed for 11 of identified
CNVs: 3 occurred de novo, eight were inherited from a
healthy parent (seven maternal, one paternal). Clinical
evaluation excluded the presence of any thoracic anom-
alies in the parents of all PS patients, indeed, the parents
of patients PS11 and PS12, suspected to present a slight
form of pectoralis muscle hypoplasia, were further ex-
amined by ultrasound analysis that confirmed a normal
phenotype for all of them.
One patient (PS2) carried a duplication, dup(5)(p15.2),
resulting from translocation 46, XX, t(5;11)(p15.1;q21)
inherited from his unaffected mother. This was the only
chromosome anomaly identified by standard karyotyp-
ing, one additional PS patient presented with 47,XXY
karyotype associated with Klinefleter syndrome. Of the
fourteen identified anomalies, except for 16p13.11-p12.3
deletion and duplication in patient PS14 and PS15 re-
spectively, 12 were not present in DGV or differed from
the reported CNVs by at least 100 kbp and/or involved
at least one more gene. No newly identified CNVs
matched those reported in DECIPHER or ClinGen.
Annotation of genes within CNVs
Based on the RefSeq database, 119 genes were identified
in either duplicated or deleted regions (CNV-genes), in-
cluding CNV-encompassed genes, genes interrupted by
CNVs, and the two genes flanking CNVs on both sides.
These last genes were included in the study according to
the hypothesis that CNVs could impair their expression
by removing or duplicating or separating expression
Table 2 Genomic deletions and duplications detected in 19 patients with Poland syndrome




2 F 5p15.2 chr5:13266637-
14011580
0.74 Dup DNAH5, TRIO Mat hypoplasia (L)/upper limb
hypoplasia (L)
-
3 M 5p14.3 chr5:22187485-
22740287

















6 F 7q11.22 chr7:70182803-
70223737







0.48 Dup GLIS3 Mat agenesis (L)/upper limb
hypoplasia (L)
-
9 F 11q12.3 chr11:63185662-
63342369
0.16 Del HRASLS5, RARRES3,
HRASLS2, PLA2G16
de novo hypoplasia (R)/hand hypoplaisa,
vertebral defects
(8)
10 M 11p14.1 chr11:28131098-
28349712

















3.29 Dup NDE1, MYH11, ABCC6,
XYLT1







1.17 Del RRN3, NDE1, MYH11,
ABCC6







0.43 Dup PSMD7, GLG1 Mat agenesis (L)/upper limb
hypoplasia (L), rib defects
(1)
20 M Xp11.22 chrX:53666883-
54056673
0.39 Dup HUWE1 Mat hypoplasia (R) (1)
aGenes previously implicated in: muscle/limb/skeletal structure and/or development; blood vessel structure and/or development; cell junction organization; cell
division. bIn this case the deletion does not encompass any genes, however, since it overlaps 5′ regions of two genes, CDH6, CDH9, these genes were both
enclosed in this table as their expression could be impaired by the deletion. Inh = inheritance
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regulatory elements from the coding sequences
(Additional file 2). We investigated each CNV-gene for
mutations associated to known disorder and/or anomal-
ous phenotype through the use of available public gen-
etic databases. Only one gene, REV3L, resulted to be
recently described as associated to one patient with PS
features [23]. Thirteen genes were known disease genes
reported in OMIM.
To gain further insight into the deleterious effects of mu-
tations involving all CNV-genes, we performed a complete
analysis of phenotypes resulting from inactivation of CNV-
gene murine and zebrafish orthologs. For 34 genes, at least
one murine mutant has been reported and phenotypically
characterized. Most reported mouse mutants presented de-
fects in tissues different from those affected in PS. For each
patient, CNV-genes that could be considered as PS candi-
date genes on the basis of their expression pattern or mo-
lecular function are showed in Table 2.
Bioinformatic analysis of genes included within CNVs
All CNV-genes were analyzed by GeneCodis to search
for a significant enrichment of annotations, which can
be used as functional descriptor of the biological pro-
cesses involved in PS. Sixty-one of the total genes were
annotated using GeneCodis, unmapped genes consisted
of poorly annotated non-coding RNAs. We identified
significant enrichment of 8 biological categories (Table 3,
Fig. 1), some of them, as those concerning mechanisms
of chondrocyte and/or skeletal muscle development,
blood coagulation, and DNA binding and apoptotic pro-
cesses, relevant as candidate mechanisms contributing
to PS development.
Discussion
Here we present the first comprehensive survey of CNVs
in PS and provide a catalog of CNVs and candidate
genes possibly implicated in the PS phenotype. Most of
the novel rearrangements identified in this study were
transmitted from unaffected parents. This is expected on
the basis of incomplete penetrance observed in familial
cases [1] and indicates that these CNVs may act as sus-
ceptibility alleles rather than direct causes of PS. In our
cohort of patients, CNVs involved different genomic re-
gions and different genes, which indicates that each
identified CNV can account for single specific cases.
This lack of overlap can be due to a sampling issue, or
one may hypothesize that, if more than one CNV is re-
lated to the disease, the genes involved in these CNVs
are members of the same family and/or belong to the
same pathways. To unveil possible interplays among
identified CNV-genes, we performed a comprehensive
bioinformatic analysis of CNVs identified in our patients
(Tab. 2). This analysis showed significant enrichment of
proteins involved in cell adhesion, blood coagulation,
chondrogenesis, asymmetric development, skeletal
muscle structure, and nucleotide binding (Table 3). For
each category and/or according to their expression pat-
tern and function, we present the most relevant genes
based on their hypothetical role in PS. The complete
lack of LAMA4 caused in mice hemorrhages associated
with capillary defects, adipose tissue alteration, and
motor control impairment [24, 25]. These findings sug-
gest that the deletion of LAMA4, by inducing hemor-
rhages during embryonic development, could cause a
variety of defects, possibly including those observed in
PS patients. This hypothesis is in line with that of
Table 3 Biological processes associated with genes rearranged in patients with PS
Genes Annotations List sizea Reference Supportb Reference sizec Hyp_cd
FYN, CDH6, CDH9, FRK,
CDH12
Panther P00012: Cadherin signaling pathway
(modular enrichment)
61 140 34208 7.40x10-5
FYN, TRIO, KIF18A, MYH11,
FRK, TUBE1, ABCC6, KIAA0430,
REV3L, DNAH5, ABCC1
GO 0000166: nucleotide binding (MF)
(modular enrichment)
61 2120 34208 3.70x10-3
CDH6,HDAC2, CDH9,CDH12 Panther P00057: Wnt signaling pathway
(modular enrichment)
61 280 34208 4.05x10-3
FYN, KIF18A, HDAC2 GO 0005515: protein binding (MF); GO 0007596:
blood coagulation (BP) (modular enrichment)
61 251 34208 1.92x10-2
TRIO, LGALS12, PSMD7,
TNFRSF19
GO:0006915, apoptotic process (BP)
(modular enrichment)
61 594 34208 3.02x10-2
KIF18A, TUBE1, DNAH5 GO 0007018, microtubule-based
movement (BP)
61 90 34208 2.88x10-2
GLG1 GO 0032330: regulation of chondrocyte
differentiation (BP)
61 3 34208 4.17x10-2
MYH11 GO 0030241, skeletal muscle myosin thick
filament assembly (BP)
61 3 34208 4.17x10-2
Abbreviations: aTotal number of genes in the input CNV list. bNumber of annotated genes in the reference list. cTotal number of genes in the reference list.
dHyp_c = Corrected hypergeometric pValue using FDR procedure with a cut-off of 5% GeneCodis. BP = biological processes. MF =molecular function
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disruption of blood supply during development as causa-
tive of PS [5, 6]. The MYH11 gene, encoding the con-
tractile protein myosin, was found duplicated in patient
PS14 and deleted in patient PS15, suggesting it could be
a dosage-sensitive gene. MYH11 missense mutations
cause a dominant form of thoracic aortic aneurysm and/
or aortic dissection (AAT4, MIM132900) and Myh11
null mice exhibit dilated cardiomyopathy [26]. No pec-
toralis muscle anomalies nor PS-associated bone defects
have been reported in AAT4 patients or described in
Myh11 null mice. In our study, the cadherin signaling
pathway resulted as the most significant among all ana-
lyzed categories and, notably, the CDH12 spanned the
breakpoint of a duplication originating de novo in one
patient. Neither hereditary disease nor animal models
are known for CDH12. Glg1 null mice were found to die
shortly after birth and about 30% of the few surviving
mice had bone defects [27]. Patients with deletion of
DNAH5 exhibit randomization of left-right body asym-
metry as situs inversus, or partial transposition of the
viscera as isolated dextrocardia. Asymmetry is also a
major feature of PS and the combination of PS and iso-
lated dextrocardia was described in 11% of PS patients
[28]. DNAH5 was duplicated in patient PS2 who pre-
sented asymmetric development of pectoralis muscles
and upper limbs, although without dextrocardia. No data
have been reported on the effects of enhanced DNAH5
expression, for instance due to gene duplication, so we
cannot exclude that both mechanisms, i.e. deficiency as
well as enhancement of DNAH5 function, may induce
asymmetric development. Asymmetric development was
also observed in mice carrying inactivation of the Rrn3
gene [29]. The SGCG gene is associated with a recessive
form of limb-girdle muscular dystrophy (LGMD2C,
MIM253700). Of note, both PS and LGMD2C affect
muscles of the limb-girdle.
An attractive candidate gene is TRIO, whose complete
absence in mice causes embryonic lethality associated
with abnormal development of skeletal muscle and
neural tissues. Indeed, Trio deficiency caused a specific
defect of myogenesis resulting in anomalies of skeletal
muscle formation [30].
In fact, after consulting available genetic databases,
OMIM, and PubMed, no mutations in any of the above
mentioned genes have been previously reported as caus-
ing a phenotype resembling that showed by PS patients,
except for one, the REV3L gene [23].
Mutations in the REV3L gene have been recently asso-
ciated with Möbius syndrome (MBS) [23], a rare con-
genital cranial dysinnervation disorder characterized by
facial palsy and variable other congenital anomalies, in-
cluding pectoralis muscle hypoplasia. Thomas-Roca and
collaborators showed that mutations in REV3L are re-
sponsible for a proportion of MBS patients with highly
variable clinical features and no obvious genotype–
phenotype correlations. Accordingly, the pectoralis
muscle agenesis was observed in only one among the
three MBS patients carrying heterozygous REV3L
Fig. 1 Graphical representation of the possible interrelationship among the CNV-genes. In this figure, CNV-genes (light blue rounded nodes) and
enriched categories (green diamonds) identified by GeneCodis analysis and their possible relantionships are visualized by Cytoscape tool
Vaccari et al. BMC Medical Genetics  (2016) 17:89 Page 6 of 8
mutations [23]. The REV3L gene encodes a protein act-
ing as catalytic subunit of DNA polymerase z, an error-
prone DNA polymerase with a key role in replication of
damaged DNA [31, 32]. In the absence of REV3L [33],
unrepaired DNA damage triggers apoptosis via the accu-
mulation of double-stranded DNA breaks. To explain
the variability of phenotypes associated to the identified
REV3L mutations in the MBS, Thomas-Roca and collab-
orators hypothesized that REV3L deficiency may result
in a stochastic ablation of cell lineages during embryonic
development, caused by replicative stress at endogenous
DNA lesions and consequent DNA damage responses.
According to this hypothesis, the appearance of the de-
scribed PS-MBS associated phenotype in one REV3L
mutation carrier may represent a very rare stochastic
event. The description of a case carrying a deletion af-
fecting the REV3L gene and showing a complex pheno-
type including PS without any apparent MBS signs
(patient PS5) may support the hypothesis of mechanisms
leading REV3L mutations to cause variable phenotypes
but also seems to support a direct role of REV3L gene in
pectoralis muscle development.
Conclusion
Data obtained by standard karyotype and array-CGH ana-
lyses in our cohort of 120 patients suggest that chromo-
some anomalies, duplications and deletions, are a rare
cause of PS. Most of identified CNVs are inherited by un-
affected parents, thus suggesting they could act as modi-
fiers and represent risk factors of PS. Genes overlapped by
the identified CNVs are enriched in functional categories
and pathways involved in cell-cell adhesion, DNA binding
and apoptosis processes, suggesting these processes as
playing a role in PS development and indicating the identi-
fied genes as candidates for further evaluation in functional
studies or mutation screening in other patients by direct
sequencing or exome sequencing.
Additional files
Additional file 1: Figure S1. Quantitative polymerase chain reaction.
In the Figure, examples of qPCR results obtained from three PS patients
carrying three different CNVs are shown. A) Patient PS16: primers were
designed to amplify a region encompassed by the duplication
(chr16:74,313,856-74,313,966) and a 5′ flanking region (chr16:73,857,457-
73,857,556); B) patient PS3: primers were designed to amplify a region
encompassed by the duplication (chr5:22,539,039-22,539,170) and a 5′
flanking region (chr5:21,756,984-21,757,122); C) Patient PS10: primers were
designed to amplify a region encompassed by the deletion
(chr11:28,126,119-28,126,268) and a 5′ flanking region (chr11:28,075,866-
28,076,003). Fold change of about 1 is expected for a diploid sample,
about 0.5 for a haploid sample, and about 2.0 for a triploid sample. ctr:
genomic DNA from one healthy adult used as control. (TIF 1168 kb)
Additional file 2: Table S2. Annotated CNV-genes of PS patients.
DUP = gene encompassed by a duplication; DEL = gene encompassed
by a deletion; CNV-flanking gene = gene flanking a CNV; DUP-INTERRUPT
= gene overlapping a duplication breakpoint. (DOCX 17.5 kb)
Abbreviations
Array-CGH: Array-comparative genomic hybridization; CNVs: Copy number
variations; PS: Poland Syndrome; qPCR: Quantitative polymerase chain
reaction
Acknowledgments
The authors wish to thank Dr G. Gimelli from the Medical Genetics Unit,
Istituto Giannina Gaslini, Genoa, Italy, for providing scientific advice; Dr A.
Capurro for revision of manuscript; the families and the AISP (Associazione
Italiana Sindrome di Poland) for their participation and cooperation with this
study.
Funding
Funding for this research was provided by Italian Ministero della Salute
(Project N. RF-2010-2314356 to A.P.; “Cinque per Mille” and Ricerca Corrente
to R.R.), by University of Genoa “Progetto Ricerca Ateneo” (to A.P. and R.R.),
and by Fondazione CARIGE.
Availability of data and materials
The authors declare that the data supporting the findings of this study are
available within the article and its Additional files.
The databases used for this study have open access and their direct links can
be found in the “Methods” section.
Authors’ contributions
Conceived and designed the work: RR and AP. Carried out the clinical
evaluation of the patients: CMV, MT, MTD, MVR, MV, FS, NC, MFB, AB, and ML.
Performed the experiments: ET, SG, SB and IM. Contributed reagents,
materials, analysis tools: ET, SG, AP, RR. Analysed the data: AP, CMV, MA,
MGC. Wrote the paper: AP and RR. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not relevant.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of the Giannina Gaslini
Institute (Protocol number: RR_AP IGG 001). Written informed consent for
analyses was obtained from all participating families, with the parents giving
consent for themselves and on behalf of their minor children.
Author details
1Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics,
Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.
2Medical Genetics Unit, Istituto Giannina Gaslini, Genoa, Italy. 3Pediatric
Surgery Unit and Airway Team, Istituto Giannina Gaslini, Genoa, Italy.
4Department of Genetic Medicine and Development, Geneva University
Medical School, Geneva, Switzerland. 5Plastic and Reconstructive Surgery,
Pediatric Surgery Unit, Istituto Giannina Gaslini, Genoa, Italy. 6Radiology Unit,
Istituto Giannina Gaslini, Genoa, Italy. 7Reconstructive Microsurgery and Hand
Surgery Unit, Istituto Giannina Gaslini, Genoa, Italy. 8Medical Genetics Unit,
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.
9U.O.S.D. Epidemiology and Biostatistics, Istituto Giannina Gaslini, Genoa, Italy.
10Medical Genetics Unit, Istituto Giannina Gaslini, via G. Gaslini 5, 16148
Genoa, Italy. 11Present Address: Department of Pediatric Cardiology and
Cardiac Surgery, Bambino Gesù Children’s Hospital, Rome, Italy.
Received: 4 August 2016 Accepted: 15 November 2016
References
1. Baban A, Torre M, Costanzo S, Gimelli S, Bianca S, Divizia MT, Senes FM,
Garavelli L, Rivieri F, Lerone M, et al. Familial Poland anomaly revisited. Am J
Med Genet A. 2012;158a(1):140–9.
2. Catena N, Divizia MT, Calevo MG, Baban A, Torre M, Ravazzolo R, Lerone M,
Senes FM. Hand and upper limb anomalies in Poland syndrome: a new
proposal of classification. J Pediatr Orthop. 2012;32(7):727–31.
Vaccari et al. BMC Medical Genetics  (2016) 17:89 Page 7 of 8
3. Freire-Maia N, Chautard EA, Opitz JM, Freire-Maia A, Quelce-Salgado A. The
Poland syndrome-clinical and genealogical data, dermatoglyphic analysis,
and incidence. Hum Hered. 1973;23(2):97–104.
4. McGillivray BC, Lowry RB. Poland syndrome in British Columbia: incidence
and reproductive experience of affected persons. Am J Med Genet. 1977;
1(1):65–74.
5. Bavinck JN, Weaver DD. Subclavian artery supply disruption sequence:
hypothesis of a vascular etiology for Poland, Klippel-Feil, and Mobius
anomalies. Am J Med Genet. 1986;23(4):903–18.
6. Beer GM, Kompatscher P, Hergan K. Poland’s syndrome and vascular
malformations. Br J Plast Surg. 1996;49(7):482–4.
7. Valasek P, Theis S, DeLaurier A, Hinits Y, Luke GN, Otto AM, Minchin J, He
LW, Christ B, Brooks G, et al. Cellular and molecular investigations into the
development of the pectoral girdle. Dev Biol. 2011;357(1):108–16.
8. Vaccari CM, Romanini MV, Musante I, Tassano E, Gimelli S, Divizia MT, Torre
M, Morovic CG, Lerone M, Ravazzolo R, et al. De novo deletion of
chromosome 11q12.3 in monozygotic twins affected by Poland Syndrome.
BMC Med Genet. 2014;15:63.
9. Tassano E, Mirabelli-Badenier M, Veneselli E, Puliti A, Lerone M, Vaccari CM,
Morana G, Porta S, Gimelli G, Cuoco C. Clinical and molecular
characterization of a patient with interstitial 6q21q22.1 deletion. Mol
Cytogenet. 2015;8:31.
10. Georgieva L, Rees E, Moran JL, Chambert KD, Milanova V, Craddock N,
Purcell S, Sklar P, McCarroll S, Holmans P, et al. De novo CNVs in bipolar
affective disorder and schizophrenia. Hum Mol Genet. 2014;23(24):6677–83.
11. Silversides CK, Lionel AC, Costain G, Merico D, Migita O, Liu B, Yuen T,
Rickaby J, Thiruvahindrapuram B, Marshall CR, et al. Rare copy number
variations in adults with tetralogy of Fallot implicate novel risk gene
pathways. PLoS Genet. 2012;8(8):e1002843.
12. Striano P, Coppola A, Paravidino R, Malacarne M, Gimelli S, Robbiano A,
Traverso M, Pezzella M, Belcastro V, Bianchi A, et al. Clinical significance of rare
copy number variations in epilepsy: a case-control survey using microarray-
based comparative genomic hybridization. Arch Neurol. 2012;69(3):322–30.
13. Tassano E, Gimelli S, Divizia MT, Lerone M, Vaccari C, Puliti A, Gimelli G.
Thrombocytopenia-absent radius (TAR) syndrome due to compound
inheritance for a 1q21.1 microdeletion and a low-frequency noncoding
RBM8A SNP: a new familial case. Mol Cytogenet. 2015;8:87.
14. Verbitsky M, Sanna-Cherchi S, Fasel DA, Levy B, Kiryluk K, Wuttke M, Abraham
AG, Kaskel F, Kottgen A, Warady BA, et al. Genomic imbalances in pediatric
patients with chronic kidney disease. J Clin Invest. 2015;125(5):2171–8.
15. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP,
Church DM, Crolla JA, Eichler EE, Epstein CJ, et al. Consensus statement:
chromosomal microarray is a first-tier clinical diagnostic test for individuals
with developmental disabilities or congenital anomalies. Am J Hum Genet.
2010;86(5):749–64.
16. Rossi PIA, Vaccari CM, Terracciano A, Doria-Lamba L, Facchinetti S, Priolo M,
Ayuso C, De Jorge L, Gimelli S, Santorelli FM. The metabotropic glutamate
receptor 1, GRM1: Evaluation as a candidate gene for inherited forms of
cerebellar ataxia. J Neurol. 2010;257(4):598–602.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods.
2001;25(4):402–8.
18. Tabas-Madrid D, Nogales-Cadenas R, Pascual-Montano A. GeneCodis3: a
non-redundant and modular enrichment analysis tool for functional
genomics. Nucleic Acids Res. 2012;40(Web Server issue):W478–83.
19. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new
features for data integration and network visualization. Bioinformatics. 2011;
27(3):431–2.
20. Silengo M, Lerone M, Seri M, Boffi P. Lower extremity counterpart of the
Poland syndrome. Clin Genet. 1999;55(1):41–3.
21. de Kovel CG, Trucks H, Helbig I, Mefford HC, Baker C, Leu C, Kluck C, Muhle H,
von Spiczak S, Ostertag P, et al. Recurrent microdeletions at 15q11.2 and 16p13.
11 predispose to idiopathic generalized epilepsies. Brain. 2010;133(Pt 1):23–32.
22. Stefansson H, Meyer-Lindenberg A, Steinberg S, Magnusdottir B, Morgen K,
Arnarsdottir S, Bjornsdottir G, Walters GB, Jonsdottir GA, Doyle OM, et al.
CNVs conferring risk of autism or schizophrenia affect cognition in controls.
Nature. 2014;505(7483):361–6.
23. Tomas-Roca L, Tsaalbi-Shtylik A, Jansen JG, Singh MK, Epstein JA, Altunoglu
U, Verzijl H, Soria L, van Beusekom E, Roscioli T, et al. De novo mutations in
PLXND1 and REV3L cause Mobius syndrome. Nat Commun. 2015;6:7199.
24. Thyboll J, Kortesmaa J, Cao R, Soininen R, Wang L, Iivanainen A, Sorokin L,
Risling M, Cao Y, Tryggvason K. Deletion of the laminin alpha4 chain leads
to impaired microvessel maturation. Mol Cell Biol. 2002;22(4):1194–202.
25. Vaicik MK, Thyboll Kortesmaa J, Moverare-Skrtic S, Kortesmaa J, Soininen R,
Bergstrom G, Ohlsson C, Chong LY, Rozell B, Emont M, et al. Laminin alpha4
deficient mice exhibit decreased capacity for adipose tissue expansion and
weight gain. PLoS One. 2014;9(10):e109854.
26. Morano I, Chai GX, Baltas LG, Lamounier-Zepter V, Lutsch G, Kott M, Haase
H, Bader M. Smooth-muscle contraction without smooth-muscle myosin.
Nat Cell Biol. 2000;2(6):371–5.
27. Miyaoka Y, Tanaka M, Imamura T, Takada S, Miyajima A. A novel regulatory
mechanism for Fgf18 signaling involving cysteine-rich FGF receptor (Cfr)
and delta-like protein (Dlk). Development. 2010;137(1):159–67.
28. Torre M, Baban A, Buluggiu A, Costanzo S, Bricco L, Lerone M, Bianca S,
Gatti GL, Senes FM, Valle M, et al. Dextrocardia in patients with Poland
syndrome: phenotypic characterization provides insight into the
pathogenesis. J Thorac Cardiovasc Surg. 2010;139(5):1177–82.
29. Yuan X, Zhou Y, Casanova E, Chai M, Kiss E, Grone HJ, Schutz G, Grummt I.
Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption,
cell cycle arrest, and p53-mediated apoptosis. Mol Cell. 2005;19(1):77–87.
30. O’Brien SP, Seipel K, Medley QG, Bronson R, Segal R, Streuli M. Skeletal
muscle deformity and neuronal disorder in Trio exchange factor-deficient
mouse embryos. Proc Natl Acad Sci U S A. 2000;97(22):12074–8.
31. Lin W, Wu X, Wang Z. A full-length cDNA of hREV3 is predicted to encode
DNA polymerase zeta for damage-induced mutagenesis in humans. Mutat
Res. 1999;433(2):89–98.
32. Van Sloun PP, Varlet I, Sonneveld E, Boei JJ, Romeijn RJ, Eeken JC, De Wind
N. Involvement of mouse Rev3 in tolerance of endogenous and exogenous
DNA damage. Mol Cell Biol. 2002;22(7):2159–69.
33. Schenten D, Kracker S, Esposito G, Franco S, Klein U, Murphy M, Alt FW,
Rajewsky K. Pol zeta ablation in B cells impairs the germinal center reaction,
class switch recombination, DNA break repair, and genome stability. J Exp
Med. 2009;206(2):477–90.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Vaccari et al. BMC Medical Genetics  (2016) 17:89 Page 8 of 8
